companies / adcendo-com
Generated UTC · publication cutoff 2026-11-09
Insufficient cited evidence for a two-sentence summary.
verified=2026-05-16 json
| total_raised | 150,000,000150.0M | ○ |
|---|---|---|
| founded | 2021 | |
| hq | Copenhagen, Denmark | |
| industry | unknown | |
| stage | series-b+ |
Adcendo develops a new generation of antibody-drug conjugates engineered for cancers with high unmet medical need. It targets cancer patients who lack adequate treatment options. Its programs aim to convert ADC science into clinically differentiated medicines with meaningful outcomes.
No cited completed company acquisition recorded.
Dated disclosures. Customer relationships and classifications are historical; ARR is separate from revenue.
No cited disclosure recorded: named customer, disclosed revenue, ARR, count, B2B / B2C, sector, go-to-market.
No cited valuation with an explicit basis is recorded.
Historical post-money / actual annual or stated TTM revenue. Same currency; economic valuation date within 90 days of revenue period end, inclusive. No FX, ARR, annualized revenue, estimates or projections. Conflicts and ambiguous ties are withheld.
No qualifying pair recorded.
| date | type | amount | lead | src |
|---|---|---|---|---|
| 2024-11-01 | series-b | 135,000,000135.0M | null | ○ |
LiteSpeed, WordPress 7.0, LiteSpeed Cache, Google Analytics, Google Tag Manager, FitVids.JS 4.27.6, jQuery Migrate 3.4.1, Easy Pie Chart, DoubleClick Floodlight, Cookiebot, Onsen UI, Zepto
| fact | status | src |
|---|---|---|
| Series B, $135.0M | attributed | ○ |
| existence | sourced | WEB |
| description | self-reported | WEB |
| date | fact | change | src |
|---|---|---|---|
| 2026-10-17provenance_existence: self-reported → sourced, WEB 2026-10-17 | provenance_existence | self-reported → sourced | WEB 2026-10-17 |
Records begin 2026-09-24. all_changes